An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications

Pathobiology

Volumn 80, Issue 3, 2013, Pages 111-118

  Vörös, András ^a   Csörgö, Erika ^a   Nyári, Tibor ^a   Cserni, Gábor ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

Author keywords

Breast cancer; Core biopsy; Ki 67; Proliferation marker; Reproducibility

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIRUBICIN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CORE BIOPSY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOLOGIST; PRIORITY JOURNAL; REPRODUCIBILITY;

EID: 84871202260     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000343795     Document Type: Article

References (33)

1. Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP: Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012; 132: 895-915.
2. Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A: Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009; 11: 205.
3. Rahmanzadeh R, Hüttmann G, Gerdes J, Scholzen T: Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif 2007; 40: 422-430.
4. Beresford MJ, Wilson GD, Makris A: Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006; 8: 216.
5. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991; 138: 867-873.
6. Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, van de Vijver MJ: The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 1999; 25: 356-363.
7. Goodson WH 3rd, Moore DH 2nd, Ljung BM, Chew K, Mayall B, Smith HS, Waldman FM: The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat 2000; 59: 113-123.
8. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-183.
9. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL: Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011; 11: 486.
10. Jung SY, Han W, Lee JW, Ko E, Kim E, Yu JH, Moon HG, Park IA, Oh DY, Im SA, Kim TY, Hwang KT, Kim SW, Noh DY: Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 2009; 16: 1112-1121.
11. Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, Doughty JC, Edwards J: Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 2012; 106: 383-388.
12. Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Ikeda K, Ogawa Y, Ishikawa T, Hirakawa K: Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res 2011; 13:R122.
13. Murri AM, Hilmy M, Bell J, Wilson C, McNicol AM, Lannigan A, Doughty JC, Mc-Millan DC: The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer 2008; 99: 1013-1019.
14. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS, International Breast Cancer Study Group: Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008; 100: 207-212.
15. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A, Breast International Group Trial 1-98: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26: 5569-5575.
16. Spyratos F, Ferrero-Poüs M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V: Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 2002; 94: 2151-2159.
17. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M: Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2010; 119: 315-323.
18. Dowsett M, A'Hern R, Salter J, Zabaglo L, Smith IE: Who would have thought a single Ki67 measurement would predict long-term outcome? Breast Cancer Res DOI: 10.1186/bcr2434.
19. Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, Bragantini E, Morelli L, Cuorvo LV, Ferro A, Gasperetti F, Berlanda G, Dalla Palma P, Barbareschi M: Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol DOI: 10.1186/1746-1596-6-S1-S7.
20. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
21. Gnant M, Harbeck N, Thomssen C: St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) 2011; 6: 136-141.
22. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF, International Ki-67 in Breast Cancer Working Group: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103: 1656-1664.
23. Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z: Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Oncology 2011; 80: 269-277.
24. Fleiss JL: The measurement of interrater agreement; in Fleiss JL (ed): Statistical Methods for Rates and Proportions, ed 2. New York, Wiley and Sons, 1980, pp 212-236.
25. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
26. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Inst Cancer 2009; 101: 736-750.
27. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR: MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 2011; 127: 591-599.
28. Kubbutat MHG, Key G, Duchrow M, Schlüter C, Flad HD, Gerdes J: Epitope analysis of antibodies recognising the cell proliferation associated nuclear antigen previously defined by the antibody Ki-67 (Ki-67 protein). J Clin Pathol 1994; 47: 524-528.
29. Zabaglo L, Salter J, Anderson H, Quinn E, Hills M, Detre S, A'Hern R, Dowsett M: Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol 2010; 63: 800-804.
30. Romero Q, Bendahl PO, Klintman M, Loman N, Ingvar C, Rydén L, Rose C, Grabau D, Borgquist S: Ki67 proliferation in core biopsies versus surgical samples -a model for neo-adjuvant breast cancer studies. BMC Cancer 2011; 11: 341.
31. European Commission Working Group on Breast Screening Pathology, Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Bussolati G, Coleman D, Connolly CE, Eusebi V, De Miguel C, Dervan P, Drijkoningen R, Elston CW, Faverly D, Gad A, Jacquemier J, Lacerda M, Martinez-Penuela J, Munt D, Peterse JL, Rank F, Tsakraklides V, Sylvan M, Zafrani B: Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. Virchows Arch 1999; 434: 3-10.
32. Varga Zs, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, Obermann E, Ohlschlegel C, Padberg B, Rakozy C, Sancho Oliver S, Schobinger-Clement S, Schreiber-Facklam H, Singer G, Tapia C, Wagner U, Mastropasqua M, Viale G, Lehr H-A: How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast-and Gynecopathologists. Plos One 2012; 7:e37379.
33. Wells CA, Sloane JP, Coleman D, Munt C, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Bussolati G, Connolly CE, Dervan P, Drijkoningen M, Ellis IO, Elston CW, Eusebi V, Faverly D, Heikkila P, Holland R, Jacquemier J, Lacerda M, Martinez-Penuela J, De Miguel C, Peterse JL, Rank F, Reiner A, Saksela E, Sigal-Zafrani B, Sylvan M, Borisch B, Cserni G, Decker T, Kerner H, Kulka J, Regitnig P, Sapino A, Tanous AM, Thorstenson S, Zozaya E, European Working Group for Breast Screening Pathology: Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union -an interlaboratory study. Virchows Arch 2004; 445: 119-128.